DENVER, Colo., Oct 18, 2023 (www.247marketnews.com)- Ardelyx Inc (NASDAQ: ARDX) announced, after yesterday’s market close, that the U.S. Food and Drug Administration (FDA) approved XPHOZAH(tenapanor), the first and only phosphate absorption inhibitor, to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
The XPHOZAH commercial product launch is expected to start in November and will be aided by an additional $50 million in committed debt financing, at Ardelyx’s election, subject to SLR credit approval, which may be further increased by an additional $50 million.
Ardelyx is trading at $3.85, up $0.40 (+11.59%), on 11.2M premarket shares traded.
Its 52-week range is $1.16 to $5.125. It hit a premarket high of $4.31 and its next key inflection points are $3.99 and $4.24, while the first key support is $3.80.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
